Answers are grounded in this paper and cite their sources.
Immunoglobulin A vasculitis (IgAV) is the most common pediatric systemic small-vessel vasculitis, with renal involvement directly determining long-term prognosis; yet no etiology-targeted interventions are clinically available. Butyrate, a gut microbiota-derived metabolite that regulates mucosal immune homeostasis, has unclear mechanisms underlying its effects on IgAV-associated multiorgan damage. Here we show that butyrate-producing microbiota are specifically depleted in children with active IgAV. Among seven major short-chain fatty acids, only butyrate is significantly decreased and tends to be negatively correlated with disease activity and renal injury indices. Using an ovalbumin-induced IgAV rat model, we demonstrate that sodium butyrate and Clostridium butyricum both reduce IgA immune complex deposition and multi-organ inflammatory infiltration via GPR43, synergistically repairing the intestinal barrier, suppressing NF-κB/NLRP3 activation and IL-6/STAT3-dependent Tfh17 differentiation, and inhibiting aberrant IgA production. These findings reveal a gut dysbiosis–butyrate deficiency–IgAV pathogenesis cascade, supporting butyrate-based preparations as a promising etiology-targeted intervention for IgAV.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: